EconomyNovo Nordisk seeks to future-proof business as investors fret over pipeline

Novo Nordisk CEO Mike Doustdar tried to reassure investors that the drugmaker can rebuild its pipeline. He pledged to speed up research efforts as the company seeks to strengthen its future prospects. An upgraded outlook for 2026, however, did not improve investor sentiment. The concerns center on whether Novo Nordisk has enough future medicines in development to support confidence in the business.